How much cash does Relmada Therapeutics, Inc. generate?

Relmada Therapeutics, Inc. (RLMD) generated -$42.8M in operating cash flow over the trailing twelve months.

What is Relmada Therapeutics, Inc.'s free cash flow?

After $182.1M of capital expenditures, Relmada Therapeutics, Inc.'s free cash flow was -$209.9M over the trailing twelve months, down 116.5% year over year.

Where does Relmada Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Relmada Therapeutics, Inc. RLMD Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$58.88M+22.2%	-$57.39M+28.3%	-$56.17M+35.0%	-$67.81M+21.8%	-$75.71M+19.7%
Stock-based compensation	$11.29M-55.7%	$13.91M-53.9%	$18.26M-45.2%	$22.6M-38.6%	$25.46M-37.5%
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	——	——	——	——	——
Change in prepaid expenses	——	——	——	——	——
Net gains (losses) on investments	-$297.57K—	$398.25K—	——	——	——
Net cash from operating activities	-$42.79M+24.7%	-$45.79M+11.5%	-$39.99M+24.8%	-$49.92M-3.6%	-$56.79M-17.8%
Purchases of investments	$232.86M+4,093%	$83.83M+594%	$1.7M-96.2%	$4.58M-91.4%	$5.55M-91.1%
Proceeds from maturities/sales of investments	$34.13M-45.3%	$35.69M-43.9%	$41.83M-54.9%	$54.1M-39.1%	$62.42M-25.0%
Acquired in-process research and development	$23.02M-48.6%	$26.88M-41.8%	$29.81M-40.3%	$36.92M-25.0%	$44.82M-14.2%
Net cash from investing activities	-$198.73M-449%	-$48.14M-193%	$40.14M-16.3%	$49.53M+38.8%	$56.86M+163%
Repurchases of common stock	——	——	——	——	——
Proceeds from issuance of common stock	$230.23M+883%	$93.64M+37,849%	$70.59M—	$46.82M—	$23.41M—
Net cash from financing activities	——	——	——	——	——
Net increase (decrease) in cash	——	——	——	——	——
Stock-based compensation	$12.19M-52.1%	$14.81M-50.9%	$18.26M-45.2%	$22.6M-38.6%	$25.46M-37.5%
Increase (Decrease) in Prepaid Expense	——	——	——	——	——
Issuance Of Restricted Common Stock	——	——	——	——	——
Net realized gains (losses)	-$152.03K-140%	-$79.21K-121%	$69.56K+102%	$298.83K+109%	$384.75K+112%
Realized Lossgain On Shortterm Investments	——	——	——	——	——
Stock Appreciation Rights Compensation	——	——	——	$29.88K—	$6.39K—
Unrealized Lossgain On Shortterm Investments	——	——	——	——	——
Payments to Acquire Short-Term Investments	$232.86M+4,093%	$83.83M+594%	$1.7M-96.2%	$4.58M-91.4%	$5.55M-91.1%
Proceeds From Sale Of Short Term Investments	$34.13M-45.3%	$35.69M-43.9%	$41.83M-54.9%	$54.1M-39.1%	$62.42M-25.0%
Payments Of Stock Issuance Costs	$120.42K-57.0%	$73.02K-74.6%	$227.25K+63.2%	$298.6K+302%	$280.34K+184%
Cashless Exercise Of Warrants	——	——	——	——	——
Effective Income Tax Rate Reconciliation Changes In Unrecognized Tax Benefits Percentage	——	——	——	——	——
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost	——	——	——	——	——
General and administrative costs	$37.33M+8.8%	$32.22M-14.6%	$28.04M-32.8%	$33.6M-20.2%	$34.3M-25.9%
Investment Income Interest	$1.92M-34.3%	$1.4M-60.5%	$1.66M-59.8%	$2.27M-50.6%	$2.91M-41.7%
Other Income - Net	$1.47M-57.0%	$1.72M-56.2%	$1.67M-67.7%	$2.72M-40.5%	$3.41M-19.5%
Outstanding Shares Percentage	——	——	——	——	——
Payments For Fees	——	——	——	——	——
Percentage Of Outstanding Shares	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period	——	——	——	——	——
Upon redemption of Accenture Holdings plc ordinary shares	——	——	——	——	——
Unrealized Gain (Loss) on Investments	-$297.57K—	$398.25K—	——	——	——
Warrant To Purchase Shares Of Common Stock	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Relmada Therapeutics, Inc. generate?: Relmada Therapeutics, Inc. (RLMD) generated -$42.8M in operating cash flow over the trailing twelve months.
What is Relmada Therapeutics, Inc.'s free cash flow?: After $182.1M of capital expenditures, Relmada Therapeutics, Inc.'s free cash flow was -$209.9M over the trailing twelve months, down 116.5% year over year.
Where does Relmada Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.